Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.
Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.
Barclays' upgrade of PTC Therapeutics to Overweight has spotlighted the biotech firm's valuation, with shares showing strong momentum but questions lingering over its path to profitability and reliance on a narrow drug portfolio.
Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.
Apex Fintech Solutions launches an 'agentic' AI suite designed to let business leaders prototype wealth management features without coding, promising to slash development time. While hailed as a potential game-changer for innovation, industry experts caution that the rush to adopt such tools must be balanced with robust oversight and firm-wide governance to avoid siloed risks and operational pitfalls.
Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.
ARK Invest's founder capitalized on recent market weakness to increase holdings in three of her flagship disruptive innovation picks, signaling continued conviction despite sector volatility.
The AI-as-a-Service (AIaaS) market is witnessing significant growth, fueled by cloud innovation and corporate demand for scalable AI solutions. While data privacy remains a hurdle, the integration of generative AI and tailored platforms is accelerating adoption across industries.
Summit Therapeutics (SMMT) finds itself at a crossroads, with its stock down over 30% in the past year. Conflicting signals from valuation models paint a complex picture: is the biotech firm dramatically overvalued on traditional metrics, or deeply undervalued based on future cash flows?
Shares of antibody discovery firm AbCellera Biologics plunged 16.8% last week, reigniting debate over its true worth. While a discounted cash flow model suggests deep undervaluation, its sky-high price-to-sales ratio paints a starkly different picture, leaving investors to navigate conflicting signals in a volatile biotech market.
In a major policy shift, the CFTC under new Chairman Michael Selig is drafting a comprehensive rulebook for event contracts, aiming to bring regulatory certainty to the fast-growing prediction market industry while fostering 'permissionless innovation.'
AppFolio Inc. reported a 22% year-over-year revenue surge in its fourth quarter, driven by AI innovation and premium product adoption, while navigating industry-wide cost pressures. The company also issued optimistic guidance for 2026.
Regeneron Pharmaceuticals' shares have softened in recent weeks, lagging behind broader market gains. A deep dive into valuation metrics, including DCF analysis and P/E ratios, suggests the biotech giant may be significantly undervalued. We examine the numbers behind the headlines and what they mean for investors.
Once a symbol of tech retrenchment, San Francisco's Showplace Square is undergoing a profound transformation. Major leases by AI firms Together AI and Physical Intelligence, coupled with Vanderbilt University's planned campus, are redefining the neighborhood as a nexus for technology, education, and innovation, offering a significant boost to the city's office recovery narrative.
A new report reveals a stark divergence in the U.S. housing market: while high rates cool mainstream activity, ultra-luxury sales above $10 million surged to a record $38.6 billion in 2025, driven by new wealth creation and a flight to tangible assets.
Powersports giant Polaris unveils an industry-first active suspension system in its flagship RZR, alongside approving its 31st consecutive annual dividend increase, signaling a dual focus on innovation and shareholder returns amid portfolio restructuring.
Craig-Hallum and Northland Securities have both lowered price targets for MiMedx Group (MDXG), citing near-term uncertainty following new CMS billing guidance for skin substitute products, though both firms maintain positive long-term ratings.
A significant reset in analyst price targets for iRhythm Holdings (IRTC) is prompting investors to reassess the cardiac monitoring firm's risk-reward profile. This shift reflects evolving views on reimbursement headwinds, competitive pressures, and long-term growth catalysts in the digital health sector.
Abbott Laboratories moves to acquire cancer-testing leader Exact Sciences in a landmark deal, signaling a strategic shift toward high-growth diagnostics while simultaneously restructuring its challenged Nutrition business.
